Abdel-Nabi H H, Schwartz A N, Wechter D G, Higano C S, Ortman-Nabi J A, Unger M W
Department of Radiology, Veterans Administration Medical Center, University of Washington, Seattle.
World J Surg. 1991 Jan-Feb;15(1):122-7. doi: 10.1007/BF01658982.
We have evaluated the role of In-111 anti-CEA (carcinoembryonic antigen) monoclonal antibody ZCE 025 in 8 patients. Three patients had a confirmed diagnosis of gastric carcinoma. Three had a confirmed diagnosis of pancreatic carcinoma. Two patients had elevated serum levels of CEA with no known primary. Each patient received 5.5 mCi In-111 ZCE 025 infused at doses of 10-80 mg. Planar and single photon emission computed tomography (SPECT) imaging at 3 and 7 days after infusion detected 9 of 12 known tumor sites and all 5 of the previously identified sites of metastasis. In-111 ZCE 025 MoAb imaging also found 6 previously unsuspected tumor sites and changed the preoperative evaluation in 50% of the patients studied. It changed the clinical management in 2 patients and established the site of primary involvement in 2 others. There were no clinical or biochemical reactions. In-111 ZCE 025 monoclonal antibody scintigraphy is a useful adjunct in the evaluation of patients with either gastric or pancreatic carcinoma. It may have a beneficial impact on the surgical decision making in these patients.
我们评估了铟 - 111标记的抗癌胚抗原（CEA）单克隆抗体ZCE 025在8例患者中的作用。3例患者确诊为胃癌。3例确诊为胰腺癌。2例患者血清CEA水平升高但原发灶不明。每位患者接受5.5毫居里的铟 - 111 ZCE 025，以10 - 80毫克的剂量静脉输注。输注后3天和7天进行的平面及单光子发射计算机断层扫描（SPECT）成像检测到了12个已知肿瘤部位中的9个以及所有5个先前确定的转移部位。铟 - 111 ZCE 025单克隆抗体成像还发现了6个先前未怀疑的肿瘤部位，并改变了50%接受研究患者的术前评估。它改变了2例患者的临床管理，并确定了另外2例患者的原发受累部位。未出现临床或生化反应。铟 - 111 ZCE 025单克隆抗体闪烁扫描术是评估胃癌或胰腺癌患者的一种有用辅助手段。它可能对这些患者的手术决策产生有益影响。
